NASDAQ:CGON

CG Oncology (CGON) Stock Price, News & Analysis

$36.65
+3.11 (+9.27%)
(As of 12:27 PM ET)
Today's Range
$33.55
$36.88
50-Day Range
$33.54
$47.93
52-Week Range
$28.55
$50.23
Volume
215,923 shs
Average Volume
624,316 shs
Market Capitalization
$2.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.75

CG Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
68.5% Upside
$61.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12.66 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.59) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.63 out of 5 stars

Medical Sector

850th out of 910 stocks

Biological Products, Except Diagnostic Industry

146th out of 153 stocks

CGON stock logo

About CG Oncology Stock (NASDAQ:CGON)

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

CGON Stock Price History

CGON Stock News Headlines

CG Oncology, Inc. (CGON)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
CG Oncology Inc (CGON)
CGON CG Oncology, Inc.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
CG Oncology, Inc.
CG Oncology Inc CGON
See More Headlines
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/23/2024
Next Earnings (Estimated)
6/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.75
High Stock Price Target
$75.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+84.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$200,000.00
Price / Sales
11,175.53
Book Value
($1.94) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.24 billion
Optionable
Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Arthur Kuan (Age 33)
    Chairman & CEO
    Comp: $640.97k
  • Mr. Ambaw Bellete M.S. (Age 53)
    President & COO
    Comp: $1.06M
  • Dr. Vijay Kasturi M.D. (Age 56)
    Chief Medical Officer
    Comp: $212.24k
  • Ms. Corleen M. Roche (Age 57)
    CFO & Secretary
  • Ms. Amy Steele
    Vice President of Finance, Accounting & Administration
  • Mr. Swapnil Bhargava Ph.D.
    Chief Technical Officer
  • Mr. Bing Kung
    Vice President of Corporate Development

CGON Stock Analysis - Frequently Asked Questions

Should I buy or sell CG Oncology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CG Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CGON shares.
View CGON analyst ratings
or view top-rated stocks.

What is CG Oncology's stock price target for 2024?

4 Wall Street analysts have issued 12-month price objectives for CG Oncology's stock. Their CGON share price targets range from $42.00 to $75.00. On average, they predict the company's share price to reach $61.75 in the next year. This suggests a possible upside of 68.5% from the stock's current price.
View analysts price targets for CGON
or view top-rated stocks among Wall Street analysts.

How have CGON shares performed in 2024?

CG Oncology's stock was trading at $37.17 at the start of the year. Since then, CGON shares have decreased by 1.4% and is now trading at $36.65.
View the best growth stocks for 2024 here
.

When is CG Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024.
View our CGON earnings forecast
.

What ETFs hold CG Oncology's stock?

ETFs with the largest weight of CG Oncology (NASDAQ:CGON) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC).Goldman Sachs Future Health Care Equity ETF (GDOC).

When did CG Oncology IPO?

CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at a price of $19.00 per share.

When did the company's quiet period expire?

CG Oncology's quiet period expired on Tuesday, March 5th. CG Oncology had issued 20,000,000 shares in its initial public offering on January 25th. The total size of the offering was $380,000,000 based on an initial share price of $19.00. During the company's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of CG Oncology?

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGON) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners